CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy

Aims: Sarcomeric gene mutations frequently underlie hypertrophic cardiomyopathy (HCM), a prevalent and complex condition leading to left ventricle thickening and heart dysfunction. We evaluated isogenic genome-edited human pluripotent stem cell-cardiomyocytes (hPSC-CM) for their validity to model, a...

Full description

Bibliographic Details
Main Authors: Mosqueira, Diogo, Mannhardt, Ingra, Bhagwan, Jamie R., Lis-Slimak, Katarzyna, Katili, Puspita, Scott, Elizabeth, Hassan, Mustafa, Prondzynski, Maksymilian, Harmer, Stephen C., Tinker, Andrew, Smith, James G.W., Carrier, Lucie, Williams, Philip M., Gaffney, Daniel, Eschenhagen, Thomas, Hansen, Arne, Denning, Chris
Format: Article
Published: Oxford University Press 2018
Subjects:
Online Access:https://eprints.nottingham.ac.uk/51099/
_version_ 1848798415657369600
author Mosqueira, Diogo
Mannhardt, Ingra
Bhagwan, Jamie R.
Lis-Slimak, Katarzyna
Katili, Puspita
Scott, Elizabeth
Hassan, Mustafa
Prondzynski, Maksymilian
Harmer, Stephen C.
Tinker, Andrew
Smith, James G.W.
Carrier, Lucie
Williams, Philip M.
Gaffney, Daniel
Eschenhagen, Thomas
Hansen, Arne
Denning, Chris
author_facet Mosqueira, Diogo
Mannhardt, Ingra
Bhagwan, Jamie R.
Lis-Slimak, Katarzyna
Katili, Puspita
Scott, Elizabeth
Hassan, Mustafa
Prondzynski, Maksymilian
Harmer, Stephen C.
Tinker, Andrew
Smith, James G.W.
Carrier, Lucie
Williams, Philip M.
Gaffney, Daniel
Eschenhagen, Thomas
Hansen, Arne
Denning, Chris
author_sort Mosqueira, Diogo
building Nottingham Research Data Repository
collection Online Access
description Aims: Sarcomeric gene mutations frequently underlie hypertrophic cardiomyopathy (HCM), a prevalent and complex condition leading to left ventricle thickening and heart dysfunction. We evaluated isogenic genome-edited human pluripotent stem cell-cardiomyocytes (hPSC-CM) for their validity to model, and add clarity to, HCM. Methods and results: CRISPR/Cas9 editing produced 11 variants of the HCM-causing mutation c.C9123T-MYH7 (p.R453C-βMHC) in 3 independent hPSC lines. Isogenic sets were differentiated to hPSC-CMs for high-throughput, non-subjective molecular and functional assessment using 12 approaches in 2D monolayers and/or 3D engineered heart tissues. Although immature, edited hPSC-CMs exhibited the main hallmarks of HCM (hypertrophy, multi-nucleation, hypertrophic marker expression, sarcomeric disarray). Functional evaluation supported the energy depletion model due to higher metabolic respiration activity, accompanied by abnormalities in calcium handling, arrhythmias and contraction force. Partial phenotypic rescue was achieved with ranolazine but not omecamtiv mecarbil, while RNAseq highlighted potentially novel molecular targets. Conclusion: Our holistic and comprehensive approach showed that energy depletion affected core cardiomyocyte functionality. The engineered R453C-βMHC-mutation triggered compensatory responses in hPSC-CMs, causing increased ATP production and αMHC to energy-efficient βMHC switching. We showed that pharmacological rescue of arrhythmias was possible, while MHY7:MYH6 and mutant:wild-type MYH7 ratios may be diagnostic, and previously undescribed lncRNAs and gene modifiers are suggestive of new mechanisms.
first_indexed 2025-11-14T20:19:25Z
format Article
id nottingham-51099
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:19:25Z
publishDate 2018
publisher Oxford University Press
recordtype eprints
repository_type Digital Repository
spelling nottingham-510992020-05-04T19:35:43Z https://eprints.nottingham.ac.uk/51099/ CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy Mosqueira, Diogo Mannhardt, Ingra Bhagwan, Jamie R. Lis-Slimak, Katarzyna Katili, Puspita Scott, Elizabeth Hassan, Mustafa Prondzynski, Maksymilian Harmer, Stephen C. Tinker, Andrew Smith, James G.W. Carrier, Lucie Williams, Philip M. Gaffney, Daniel Eschenhagen, Thomas Hansen, Arne Denning, Chris Aims: Sarcomeric gene mutations frequently underlie hypertrophic cardiomyopathy (HCM), a prevalent and complex condition leading to left ventricle thickening and heart dysfunction. We evaluated isogenic genome-edited human pluripotent stem cell-cardiomyocytes (hPSC-CM) for their validity to model, and add clarity to, HCM. Methods and results: CRISPR/Cas9 editing produced 11 variants of the HCM-causing mutation c.C9123T-MYH7 (p.R453C-βMHC) in 3 independent hPSC lines. Isogenic sets were differentiated to hPSC-CMs for high-throughput, non-subjective molecular and functional assessment using 12 approaches in 2D monolayers and/or 3D engineered heart tissues. Although immature, edited hPSC-CMs exhibited the main hallmarks of HCM (hypertrophy, multi-nucleation, hypertrophic marker expression, sarcomeric disarray). Functional evaluation supported the energy depletion model due to higher metabolic respiration activity, accompanied by abnormalities in calcium handling, arrhythmias and contraction force. Partial phenotypic rescue was achieved with ranolazine but not omecamtiv mecarbil, while RNAseq highlighted potentially novel molecular targets. Conclusion: Our holistic and comprehensive approach showed that energy depletion affected core cardiomyocyte functionality. The engineered R453C-βMHC-mutation triggered compensatory responses in hPSC-CMs, causing increased ATP production and αMHC to energy-efficient βMHC switching. We showed that pharmacological rescue of arrhythmias was possible, while MHY7:MYH6 and mutant:wild-type MYH7 ratios may be diagnostic, and previously undescribed lncRNAs and gene modifiers are suggestive of new mechanisms. Oxford University Press 2018-05-08 Article PeerReviewed Mosqueira, Diogo, Mannhardt, Ingra, Bhagwan, Jamie R., Lis-Slimak, Katarzyna, Katili, Puspita, Scott, Elizabeth, Hassan, Mustafa, Prondzynski, Maksymilian, Harmer, Stephen C., Tinker, Andrew, Smith, James G.W., Carrier, Lucie, Williams, Philip M., Gaffney, Daniel, Eschenhagen, Thomas, Hansen, Arne and Denning, Chris (2018) CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. European Heart Journal . ISSN 1522-9645 Hypertrophic cardiomyopathy; Disease modelling; CRISPR/Cas9; Genome-edited human pluripotent stem cell-cardiomyocytes; R453C-βMHC https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehy249/4993867 doi:10.1093/eurheartj/ehy249 doi:10.1093/eurheartj/ehy249
spellingShingle Hypertrophic cardiomyopathy; Disease modelling; CRISPR/Cas9; Genome-edited human pluripotent stem cell-cardiomyocytes; R453C-βMHC
Mosqueira, Diogo
Mannhardt, Ingra
Bhagwan, Jamie R.
Lis-Slimak, Katarzyna
Katili, Puspita
Scott, Elizabeth
Hassan, Mustafa
Prondzynski, Maksymilian
Harmer, Stephen C.
Tinker, Andrew
Smith, James G.W.
Carrier, Lucie
Williams, Philip M.
Gaffney, Daniel
Eschenhagen, Thomas
Hansen, Arne
Denning, Chris
CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
title CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
title_full CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
title_fullStr CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
title_full_unstemmed CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
title_short CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
title_sort crispr/cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
topic Hypertrophic cardiomyopathy; Disease modelling; CRISPR/Cas9; Genome-edited human pluripotent stem cell-cardiomyocytes; R453C-βMHC
url https://eprints.nottingham.ac.uk/51099/
https://eprints.nottingham.ac.uk/51099/
https://eprints.nottingham.ac.uk/51099/